Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX Announcement – 29 April 2024
QUARTERLY ACTIVITIES & CASHFLOW REPORT
Highlights
•
•
•
•
•
•
•
•
•
Invoiced revenue of $2.08M, up significantly from previous quarters
1HFY24 revenue of $3.26M, up 55% versus the 1HFY23 revenue of $2.11M
Cash receipts from customers of $1.15M, up 9.5% from the March FY23 quarter of $1.05M
New major pharma clinical trial progressing well with $0.93M invoiced during the quarter
Operating cashflow of -$0.5M, with the result influenced by the timing of invoices vs receipts
Contracted to acquire 100% of TrialsWest Pty Ltd for $4M upfront cash consideration and
up to $4M in additional earnout consideration
Collaboration agreement signed with Tokyo Japan headquartered, Micron, Inc. to feature
Resonance Health’s imaging analysis products and services within the Japanese market
Advanced negotiations with a complementary software-medical-device partner
Cash at bank of $5.32M at the end of the quarter, and no debt
Resonance Health Ltd (ASX: RHT) (Resonance Health or Company) is pleased to release its Appendix 4C and
Quarterly Activities & Cashflow Report for the quarter ended 31 March 2024.
Corporate Strategy
The Company continues to progress its strategy of leveraging its large global footprint of imaging and clinical
trial customers to gain a greater share of spending within the clinical trial ecosystem. During the quarter the
Company both expanded its geographic reach with a Collaboration Agreement executed with Micron, Inc. in
Japan, and its product and service offering with the acquisition of TrialsWest Pty Ltd (TrialsWest).
TrialsWest Acquisition
TrialsWest is one of Australia’s most experienced and successful clinical research centres having partnered
with some of the world’s leading pharmaceutical and biotechnology companies to help bring new medicines
and vaccines to the global community. The acquisition is expected to contribute $2 million in revenue and
$0.65 million in EBITDA to the Resonance Health group, on an annualised basis (based on its projected FY24
full year trading performance).
Under the terms of the Share Sale Agreement signed with TrialsWest, the Company will pay upfront cash
consideration of $4 million (equivalent to 6 x FY24 forecast EBITDA), calculated on a cash-free debt-free basis.
A further $4 million may be payable to the TrialsWest vendors pursuant to an earnout arrangement which is
subject to EBITDA performance targets being achieved during FY24 to FY26. Total consideration of up to $8
million is payable if TrialsWest generates annual EBITDA of $1.33 million in a financial period up to and
including FY26. The transaction is expected to complete in the last quarter of FY24.
This acquisition is a key plank in the Company’s strategy of increased commercial involvement in the clinical
trial ecosystem and utilising Resonance Health’s deep-domain expertise to deliver value for our global
Resonance Health Ltd ABN: 96 006 762 492
141 Burswood Road, Burswood, WA 6100, AUSTRALIA
Postal: PO Box 71, Burswood, WA 6100, AUSTRALIA
www.resonancehealth.com
T + 61 8 9286 5300
info@resonancehealth.com
customers. The Company intends to expand TrialsWest with the addition of new clinical trial sites and
complementary acquisitions.
Collaboration with Micron
In March 2024 the Company signed a Collaboration Agreement (Agreement) with Tokyo, Japan, based
Micron, Inc. to feature Resonance Health’s imaging analysis products and services within the Japanese
market. The Agreement progresses the Company’s strategy of expanding into new geographies for both
clinical trial and diagnostic services. Japan is among the largest pharmaceutical markets in the world with
over USD $100 billion in sales in 2021 for both prescription and non-prescription pharmaceuticals. Working
with an established entity with over 20 years of experience in CRO services in the Japanese market will assist
in Resonance Health’s fast-tracking of growth in Japan for both its clinical trial and diagnostic services.
New Products & Service Enhancements
The Company also continues to invest in bringing new products to market, including a non-invasive liver
fibrosis assessment where we continue to progress our extended proof of concept trial, along with a pipeline
of product extensions and improvements including MRI shorter acquisition times, Cardiac 3T and others.
Advanced negotiations continued with complementary software-as-a-medical device (SaMD) vendors to
refer and license their technologies providing Resonance Health with the ability to both streamline workflows
and sell products to a wider audience and sell additional products to existing customers.
Major Pharma Clinical Trial
The Clinical Trial Research Agreement (CTRA) signed with a global major pharma and announced in August
2023 is progressing in line with expectations. The trial commenced recruiting participants during the quarter
and the Company invoiced $0.93M during the quarter in milestone payments. The CTRA is expected to
generate significant revenue over the last quarter of FY24 as patient recruitment continues and milestone
payment hurdles are completed. The Company has invoiced $1.98M in milestone payments so far in the trial
with a total of $6.33M to be invoiced over the course of the trial subject to it running for its expected duration
of approximately 24 months.
The delivery of services under this material services contract continues to highlight the Company’s growing
capabilities in the clinical trials ecosystem.
Financial & Operating Performance
Continued strong demand in diagnostics, clinical trials, and milestone CTRA payments contributed to invoiced
revenue of $2.08M for the quarter comparing favourably with the entire 1HFY24 revenue recorded of
$3.26M. This included $0.93M invoiced for CTRA milestones achieved in the trial during the quarter.
Cash receipts from customers of $1.15M was down from $2.1M during the Dec Quarter and up 9.5% or $0.1M
from the pcp FY23 of $1.05M. Timing differences between invoices issued and receipts was the main cause
of net negative operating cashflow being recorded for the quarter of $0.5M.
The Company’s balance sheet remains strong with a cash balance of $5.32M at the end of quarter. The
Company has no debt. The Company is also expecting to lodge its R&D tax rebate claim during the next
quarter.
With respect to item 6 of the Appendix 4C cash flow report for the quarter, payments to related parties of
approximately $86K were made during the quarter. This comprised of $36K paid to Mr Mitchell Wells for
Page 2
company secretarial and consulting services. Remuneration of $50k was paid to non-executive directors for
their service.
This announcement has been authorised for release in accordance with the delegated authority of the Board
of Directors of Resonance Health Ltd. For further information please contact:
Andrew Harrison – Chief Executive Officer
E: andrewh@resonancehealth.com
P: +61 (0)8 9286 5300
About Resonance Health
Resonance Health is an Australian healthcare technology and services company. The Company’s services are used
globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their
clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality
quantitative assessments essential in managing diseases and drug development. The Company also has a clinical trials
business including site management operations following the TrialsWest acquisition.
Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range
of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485
certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which
incorporate Artificial Intelligence (AI), include:
§ FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through noninvasive MRI-based technology, for use in the assessment of individuals with iron overload conditions.
Internationally recognised as the gold standard in LIC assessment.
§ FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in
patients, calibrated against the global gold standard, FerriScan®.
§ HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue
for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
§ HepaFatSmart ®, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liverfat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
§ LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFatAI® into a consolidated report providing accurate assessment of LIC and liver fat.
§ CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual
analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared.
The Company has a development pipeline of additional medical imaging analysis products and services, including the
MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis utilising noninvasive MRI analysis.
Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at
www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter.
Page 3
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Resonance Health Limited
ABN
Quarter ended (“current quarter”)
96 006 762 492
31 March 2024
Consolidated statement of cash flows
Current quarter
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
(a) research and development
Year to date (9
months)
$A’000
1,150
4,336
(38)
(590)
(277)
(643)
(1,001)
(2,527)
(365)
(1,387)
4
80
16
76
(511)
(655)
(10)
(220)
(43)
(106)
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
(e) staff costs
(f)
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
1.5
Interest and other costs of finance paid
1.6
Income taxes paid
1.7
Government grants and tax incentives
1.8
Other (provide details if material)
1.9
Net cash from / (used in) operating
activities
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date (9
months)
$A’000
Proceeds from disposal of:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
2.3
Cash flows from loans to other entities
2.4
Dividends received (see note 3)
2.5
Other (provide details if material)
2.6
Net cash from / (used in) investing
activities
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2
Proceeds from issue of convertible debt
securities
3.3
Proceeds from exercise of options
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
3.5
Proceeds from borrowings
3.6
Repayment of borrowings
3.7
Transaction costs related to loans and
borrowings
3.8
Dividends paid
3.9
Other:
- Lease payments
- Net payments for cash backed
guarantees
3.10
Net cash from / (used in) financing
activities
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
(53)
(326)
(55)
(113)
-
(20)
(55)
(133)
5,898
6,362
(511)
(655)
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (9
months)
$A’000
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(53)
(326)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
(55)
(133)
4.5
Effect of movement in exchange rates on
cash held
45
76
4.6
Cash and cash equivalents at end of
period
5,324
5,324
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
938
1,512
5.2
Call deposits
4,386
4,386
5.3
Bank overdrafts
5.4
Other (provide details)
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
5,324
5,898
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
Current quarter
$A'000
86
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
7.2
Credit standby arrangements
7.3
Other (please specify)
7.4
Total financing facilities
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(511)
8.2
Cash and cash equivalents at quarter end (item 4.6)
5,324
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
5,324
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
10.42
$A’000
-
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
29 April 2024
Authorised by: By the Board of Directors of Resonance Health Limited
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover